Oncology On The Go

Emphasizing the evidence-based nature of medicine, Nathan Goodyear, MD, explained that integrative oncology uses many of the same parameters and key clinical thresholds among patients undergoing treatment for a diagnosis of cancer that his conventional oncologist colleagues use. In this episode of Oncology on the Go , Goodyear, an integrative medicine physician at the Williams Cancer Institute, di...

In a conversation with CancerNetwork®, Kandace P. McGuire, MD, and Paschalia Mountziaris, MD, PhD, highlighted the use of L-Dex bioimpedance spectroscopy as a method for detecting lymphedema earlier in patients who undergo surgery for breast cancer. The experts discussed seamlessly integrating this novel modality into standard vitals workflows and detailed other considerations for improving long-t...

In a conversation with CancerNetwork®, Nathan Goodyear, MD, provided an overview of how to implement integrative modalities that may effectively supplement standard-of-care oncologic therapies. Beyond the use of intravenous vitamin C and other flagship strategies at his institution, Goodyear addressed potential misconceptions and biases surrounding integrative oncology and discussed how to re-enga...

In a conversation with CancerNetwork®, Jose G. Trevino, II, MD, FACS, spoke about the current state of the pancreatic ductal adenocarcinoma (PDAC) paradigm as well as next steps for improving the prognosis of patients who present with this disease. Throughout the discussion, Trevino outlined the roles that surgical oncologists can play in disease management, the different demographic and socioecon...

After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the  data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transp...

This episode of the collaborative podcast between Oncology on the Go and the American Psychosocial Oncology Society (APOS), hosted by Daniel C. McFarland, DO, features Michelle B. Riba, MD, and focuses on integrating psychosocial care into oncology for clinicians. The discussion emphasizes that psychosocial issues profoundly impact both quality of life and cancer-related outcomes, making their ass...

At the 2025 American Society of Hematology Annual Meeting & Exposition (ASH), CancerNetwork® sat down with a variety of researchers and clinicians to discuss potential advancements across hematologic oncology care. These experts shared their findings related to investigational therapeutic regimens and strategies that may prove impactful across different multiple myeloma, lymphoma, and leukemia...

In the most recent ONCOLOGY On the Go hosted in collaboration with the American Psychosocial Oncology Society, Daniel C. McFarland, DO, spoke with Charles S. Kamen, PhD, MPH, about health equity for sexual and gender minority groups in oncology.  Sexual and gender minority groups, who constitute approximately 9.3% of the US population, experience significant and preventable disparities across all...

As part of a visit to Georgia Cancer Center in Augusta, Georgia, CancerNetwork spoke with a variety of experts and faculty members regarding ongoing research and future initiatives dedicated to improving outcomes across different patient populations. These conversations touched upon potential developments in diseases including non–small cell lung cancer (NSCLC), multiple myeloma, and acute myeloid...

In a collaborative podcast with the American Psychosocial Oncology Society hosted by Daniel C. McFarland, DO, guests Louis P. Voigt, MD, and Yesne Alici, MD, discussed the ethical and clinical complexities of assessing decision-making capacity (DMC) in oncology, emphasizing its role as the ethical core of person-centered care. The discussion began by dissecting modern medicine’s need for formal DM...

In a conversation with CancerNetwork®, Michael Barish, PhD, spoke about an investigational CAR T-cell therapy that he and colleagues are developing as a treatment for patients with glioblastoma. He and his team designed the agent to harness chlorotoxin, an amino acid peptide toxin component of scorpion venom, as a vehicle for intratumoral delivery of therapy for this patient population. Barish, a...

The latest episode of Oncology On the Go focused on survivorship and supportive care. Stemming from conversations with leading clinicians in the field, the compilation highlights gaps and educational insights into multiple areas.  Covering topics like nutrition, oncodermatology, body image, sexual health, and mortality, these conversations explored how to truly optimize multidisciplinary cancer ca...

Following a fruitful European Society of Medical Oncology (ESMO) Congress 2025 for gastrointestinal malignancies, CancerNetwork® organized an X Spaces discussion hosted by 3 experts. They were Nicholas J. Hornstein, MD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health; Timothy Brown, MD, an assistant professor in the Department o...

As part of the European Society for Medical Oncology (ESMO) Congress 2025, CancerNetwork® spoke with a variety of experts about key takeaways from different late-breaking abstracts, oral presentations, and other sessions focused on potential advancements across cancer care. Presenting investigators highlighted updated results from clinical trials evaluating novel therapeutic strategies across diff...

In a discussion with CancerNetwork®, Anne Chiang, MD, PhD, spoke about the current treatment landscape for those with small cell lung cancer (SCLC) as well as next steps for elevating the quality of care among patients. She began by outlining the evolution of therapeutic standards in the field, with atezolizumab (Tecentriq)- and durvalumab (Imfinzi)-based regimens emerging as key frontline strateg...

In a conversation with CancerNetwork®, Jorge Cortes, MD, explored the evolution of the chronic myeloid leukemia (CML) landscape. Specifically, he highlighted how the development of ibrutinib (Gleevec) paved the way for other tyrosine kinase inhibitors (TKIs) and described where research must go next in terms of implementing fixed-duration therapy and targeting genetic abnormalities. Cortes, the di...

In a special co-branded episode between Oncology On the Go , hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program, ASTCT Talks , for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP,...

In a conversation with CancerNetwork® following the FDA approval of the gemcitabine intravesical system (Inlexzo; formerly TAR-200) for patients with high-risk, Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC), Gary Steinberg, MD, discussed how this regulatory decision may impact the treatment paradigm. Steinberg, a professor in the Department of Urology at Ru...

In the recent episode of Oncology-on-the-Go, in collaboration with the American Psychosocial Oncology Society (APOS), Daniel C. McFarland, DO, welcomes William S. Breitbart, MD, to discuss how clinicians can address patients’ existential concerns. While oncologists often focus on treatment and the drive for life, the core concern for many patients remains mortality. Breitbart’s work in meaning-cen...

At the Society of Hematologic Oncology 2025 Annual Meeting , CancerNetwork® spoke with a variety of experts about notable clinical developments and trial results across the hematologic oncology landscape. Throughout the meeting, clinicians and researchers discussed the latest data and initiatives in myelofibrosis, multiple myeloma, lymphoma, and other types of blood cancer. Francesca Palandri, MD,...

In this episode, CancerNetwork® spoke with Joseph S. Wallins, MD, MPH, cardiology fellow at Weill Cornell Medicine, about a review of cardiotoxicities associated with breast cancer treatment he coauthored in the June 2025 issue of ONCOLOGY® titled, “Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment.” Therein, he touched upon data for risk stratificati...

In a recent episode of the Oncology-on-the-Go podcast in collaboration with the American Psychosocial Oncology Society (APOS), host Daniel C. McFarland, DO, was joined by Christian J. Nelson, PhD, to discuss the often-overlooked subject of sexual health issues for men after cancer treatment. The discussion emphasized the importance of a nuanced approach to men's health, particularly in the context...

In a conversation with CancerNetwork®, Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, spoke about her new appointment as the principal investigator and director of Clinical Research at the Northwell Health unit of the Southern Texas Accelerated Research Therapeutics (START) Center for Cancer Research. Based on a strategic partnership formed between Northwell Health and START in May 2024, she will ove...

In the inaugural podcast episode created in collaboration with the American Psychosocial Oncology Society (APOS), Daniel C. McFarland, DO, and Michelle Fingeret, PhD, explored the critical, yet often overlooked, issue of body image in patients with cancer. McFarland opened the discussion by acknowledging the significant psychosocial challenges clinicians face and highlighted the therapeutic power...

In a conversation with CancerNetwork® at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference, Tiba Al Sagheer, PharmD, BCOP, BCACP; Rebecca Gonzalez, PharmD, BCOP, FASTCT; and Syeda Saba Kareem PharmD, BCOP, spoke about their presentations on managing adverse effects (AEs) across different hematologic malignancy populations. At the meeting, Al Sagheer, Gonzalez, and Kareem presented...